DK3099333T3 - Bag3 som mål for behandling af hjertesvigt - Google Patents
Bag3 som mål for behandling af hjertesvigt Download PDFInfo
- Publication number
- DK3099333T3 DK3099333T3 DK15743948.0T DK15743948T DK3099333T3 DK 3099333 T3 DK3099333 T3 DK 3099333T3 DK 15743948 T DK15743948 T DK 15743948T DK 3099333 T3 DK3099333 T3 DK 3099333T3
- Authority
- DK
- Denmark
- Prior art keywords
- bag3
- goal
- treatment
- heart failure
- heart
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461934483P | 2014-01-31 | 2014-01-31 | |
PCT/US2015/013926 WO2015117010A2 (en) | 2014-01-31 | 2015-01-30 | Bag3 as a target for therapy of heart failure |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3099333T3 true DK3099333T3 (da) | 2021-02-01 |
Family
ID=53757927
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK15743948.0T DK3099333T3 (da) | 2014-01-31 | 2015-01-30 | Bag3 som mål for behandling af hjertesvigt |
Country Status (10)
Country | Link |
---|---|
US (3) | US11236389B2 (da) |
EP (2) | EP3812473A1 (da) |
JP (3) | JP6920818B2 (da) |
CA (2) | CA3228845A1 (da) |
DK (1) | DK3099333T3 (da) |
ES (1) | ES2838804T3 (da) |
HU (1) | HUE052814T2 (da) |
PT (1) | PT3099333T (da) |
SI (1) | SI3099333T1 (da) |
WO (1) | WO2015117010A2 (da) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3099333T (pt) * | 2014-01-31 | 2020-12-24 | Univ Temple | Bag3 como alvo para terapia de insuficiência cardíaca |
WO2017031182A2 (en) | 2015-08-17 | 2017-02-23 | Temple University Of The Commonwealth System Of Higher Education | Bag3 compositions and methods |
CN105769900A (zh) * | 2016-03-22 | 2016-07-20 | 山西大学 | Bag3基因在制备抗膀胱癌药物中的应用 |
KR101804678B1 (ko) | 2016-05-30 | 2017-12-04 | 가톨릭대학교 산학협력단 | Bis 억제제 스크리닝용 마커, 이를 포함하는 스크리닝 키트 및 이를 이용한 bis 억제제 스크리닝 방법 |
IT201600069391A1 (it) * | 2016-07-04 | 2016-10-04 | Univ Degli Studi Di Salerno | Uso della proteina bag3 e suoi frammenti peptidici per il controllo dell’omeostasi vascolare |
CN109937045A (zh) * | 2016-08-11 | 2019-06-25 | 天普大学-联邦高等教育系统 | 局部缺血/再灌注损伤 |
WO2018129528A1 (en) * | 2017-01-09 | 2018-07-12 | Duke University | Methods for treating ischemic injury |
IT201700113648A1 (it) * | 2017-10-10 | 2019-04-10 | Biouniversa Srl | Anti-BAG3 antibodies as therapeutic reagent in cardiovascular diseases |
US20210024623A1 (en) | 2017-07-28 | 2021-01-28 | Intrepida Bio, Inc. | Anti-bag3 antibodies as therapeutic reagent in cardiovascular disease |
AU2019281008A1 (en) * | 2018-06-08 | 2021-01-28 | Temple University - Of The Commonwealth System Of Higher Education | Optimizing BAG3 gene therapy |
CA3119068A1 (en) | 2018-11-08 | 2020-05-14 | University Of Miami | Method of determining responsiveness to cell therapy in dilated cardiomyopathy |
US20220088127A1 (en) * | 2019-01-15 | 2022-03-24 | Temple University - Of The Commonwealth System Of Higher Education | Targeting the bag family for the treatment of neurodegenerative disease |
WO2023019272A1 (en) * | 2021-08-12 | 2023-02-16 | Temple University Of The Commonwealth System Of Higher Education | Retrograde coronary venous or sinus administration of therapeutics |
WO2023108159A1 (en) * | 2021-12-10 | 2023-06-15 | University Of Florida Research Foundation, Incorporated | Methods and compositions for treating bag-3 related cardiomyopathy with a viral vector |
WO2023147558A2 (en) * | 2022-01-28 | 2023-08-03 | Temple University - Of The Commonwealth System Of Higher Education | Crispr methods for correcting bag3 gene mutations in vivo |
WO2023205767A2 (en) * | 2022-04-22 | 2023-10-26 | Spacecraft Seven, Llc | B-cell lymphoma 2–associated anthanogene 3 (bag3) gene therapy using aav vector |
WO2023215266A1 (en) * | 2022-05-03 | 2023-11-09 | Temple University Of The Commonwealth System Of Higher Education | Bag3 and protein quality control in the brain |
WO2024059756A1 (en) * | 2022-09-16 | 2024-03-21 | Temple University Of The Commonwealth System Of Higher Education | Bag 3 methods and uses for treatment of cardiac amyloidosis |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
DE3788914T2 (de) | 1986-09-08 | 1994-08-25 | Ajinomoto Kk | Verbindungen zur Spaltung von RNS an eine spezifische Position, Oligomere, verwendet bei der Herstellung dieser Verbindungen und Ausgangsprodukte für die Synthese dieser Oligomere. |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
ATE151467T1 (de) | 1987-11-30 | 1997-04-15 | Univ Iowa Res Found | Durch modifikationen an der 3'-terminalen phosphodiesterbindung stabilisierte dna moleküle, ihre verwendung als nukleinsäuresonden sowie als therapeutische mittel zur hemmung der expression spezifischer zielgene |
US5403711A (en) | 1987-11-30 | 1995-04-04 | University Of Iowa Research Foundation | Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved |
US4907603A (en) | 1988-01-04 | 1990-03-13 | Bertha D. Chambers | Safety smoke |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
US5623065A (en) | 1990-08-13 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Gapped 2' modified oligonucleotides |
US5459255A (en) | 1990-01-11 | 1995-10-17 | Isis Pharmaceuticals, Inc. | N-2 substituted purines |
US5149797A (en) | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
US5220007A (en) | 1990-02-15 | 1993-06-15 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of RNA and production of encoded polypeptides |
US5218105A (en) | 1990-07-27 | 1993-06-08 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
US5138045A (en) | 1990-07-27 | 1992-08-11 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
US5474796A (en) | 1991-09-04 | 1995-12-12 | Protogene Laboratories, Inc. | Method and apparatus for conducting an array of chemical reactions on a support surface |
US5605662A (en) | 1993-11-01 | 1997-02-25 | Nanogen, Inc. | Active programmable electronic devices for molecular biological analysis and diagnostics |
US5670113A (en) | 1991-12-20 | 1997-09-23 | Sibia Neurosciences, Inc. | Automated analysis equipment and assay method for detecting cell surface protein and/or cytoplasmic receptor function using same |
US5700922A (en) | 1991-12-24 | 1997-12-23 | Isis Pharmaceuticals, Inc. | PNA-DNA-PNA chimeric macromolecules |
US5652355A (en) | 1992-07-23 | 1997-07-29 | Worcester Foundation For Experimental Biology | Hybrid oligonucleotide phosphorothioates |
US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
DE69425903T2 (de) | 1993-12-09 | 2001-02-15 | Thomas Jefferson University Ph | Verbindungen und verfahren zur ortsspezifischen mutation in eukaryotischen zellen |
JPH10501681A (ja) | 1994-02-22 | 1998-02-17 | ダナ−ファーバー キャンサー インスティチュート | 核酸送達システムならびにその合成および使用方法 |
US6015880A (en) | 1994-03-16 | 2000-01-18 | California Institute Of Technology | Method and substrate for performing multiple sequential reactions on a matrix |
US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
US5652356A (en) | 1995-08-17 | 1997-07-29 | Hybridon, Inc. | Inverted chimeric and hybrid oligonucleotides |
CA2864537C (en) | 2001-11-13 | 2016-11-29 | The Trustees Of The University Of Pennsylvania | A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby |
EP1323733A1 (en) * | 2001-12-28 | 2003-07-02 | Arturo Leone | BAG3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases |
US20030175958A1 (en) * | 2002-03-15 | 2003-09-18 | Reed John C. | Methods for using bag expression as a cell differentiation agent and marker |
AU2008350903B2 (en) | 2008-02-19 | 2015-04-02 | Celladon Corporation | Compositions for enhanced uptake of viral vectors in the myocardium |
WO2010138263A2 (en) | 2009-05-28 | 2010-12-02 | University Of Massachusetts | Novel aav 's and uses thereof |
WO2012087835A2 (en) * | 2010-12-22 | 2012-06-28 | Boston Biomedical Research Institute | Compositions and methods for enhancing protein folding |
WO2012107580A1 (en) | 2011-02-10 | 2012-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | In vitro diagnosis method for predicting a predisposition to cardiomyopathy |
PT3099333T (pt) | 2014-01-31 | 2020-12-24 | Univ Temple | Bag3 como alvo para terapia de insuficiência cardíaca |
WO2023019272A1 (en) | 2021-08-12 | 2023-02-16 | Temple University Of The Commonwealth System Of Higher Education | Retrograde coronary venous or sinus administration of therapeutics |
-
2015
- 2015-01-30 PT PT157439480T patent/PT3099333T/pt unknown
- 2015-01-30 CA CA3228845A patent/CA3228845A1/en active Pending
- 2015-01-30 ES ES15743948T patent/ES2838804T3/es active Active
- 2015-01-30 CA CA2975258A patent/CA2975258A1/en active Pending
- 2015-01-30 EP EP20208165.9A patent/EP3812473A1/en active Pending
- 2015-01-30 JP JP2016549334A patent/JP6920818B2/ja active Active
- 2015-01-30 HU HUE15743948A patent/HUE052814T2/hu unknown
- 2015-01-30 EP EP15743948.0A patent/EP3099333B8/en active Active
- 2015-01-30 WO PCT/US2015/013926 patent/WO2015117010A2/en active Application Filing
- 2015-01-30 DK DK15743948.0T patent/DK3099333T3/da active
- 2015-01-30 US US15/115,807 patent/US11236389B2/en active Active
- 2015-01-30 SI SI201531453T patent/SI3099333T1/sl unknown
-
2019
- 2019-10-21 JP JP2019191740A patent/JP7079761B2/ja active Active
-
2020
- 2020-05-21 US US15/929,784 patent/US11542555B2/en active Active
-
2022
- 2022-05-23 JP JP2022083707A patent/JP2022116125A/ja active Pending
- 2022-10-05 US US17/938,209 patent/US20230073246A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
PT3099333T (pt) | 2020-12-24 |
EP3099333B8 (en) | 2020-12-30 |
EP3099333B1 (en) | 2020-11-18 |
CA2975258A1 (en) | 2015-08-06 |
JP7079761B2 (ja) | 2022-06-02 |
EP3099333A4 (en) | 2017-09-06 |
HUE052814T2 (hu) | 2021-05-28 |
US20230073246A1 (en) | 2023-03-09 |
ES2838804T3 (es) | 2021-07-02 |
US20210017600A1 (en) | 2021-01-21 |
CA3228845A1 (en) | 2015-08-06 |
US11542555B2 (en) | 2023-01-03 |
JP2022116125A (ja) | 2022-08-09 |
US20170016066A1 (en) | 2017-01-19 |
JP6920818B2 (ja) | 2021-08-18 |
WO2015117010A2 (en) | 2015-08-06 |
JP2017506623A (ja) | 2017-03-09 |
SI3099333T1 (sl) | 2021-04-30 |
JP2020079235A (ja) | 2020-05-28 |
EP3812473A1 (en) | 2021-04-28 |
EP3099333A2 (en) | 2016-12-07 |
US11236389B2 (en) | 2022-02-01 |
WO2015117010A3 (en) | 2015-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3099333T3 (da) | Bag3 som mål for behandling af hjertesvigt | |
DK3377488T3 (da) | Heterocykliske forbindelser som immunomodulatorer | |
DK3472167T3 (da) | Heterocykliske forbindelser som immunomodulatorer | |
DK3394033T3 (da) | Heterocykliske forbindelser som immunmodulatorer | |
DK3389564T3 (da) | Hjerteklapprotese | |
DK3094631T3 (da) | Pyrimidinyloxybenzenderivater som herbicider | |
DK3357919T3 (da) | Aromatiske heterocykliske forbindelser som antiinflammatoriske forbindelser | |
DK3142607T3 (da) | Hjerteklapprotese | |
DK3235465T3 (da) | Implantat | |
DK3125836T3 (da) | Vejrtrækningshjæpeapparat | |
DK3125875T3 (da) | Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande | |
DK3131902T3 (da) | Forbindelser som ROR-gamma-modulatorer | |
DK3372584T5 (da) | Fremgangsmåde til fremstillingen af en diarylthiohydantoin-forbindelse | |
DK3160950T3 (da) | Herbicide propynylphenylforbindelser | |
DK3189043T3 (da) | Terapeutiske forbindelser som hæmmere af orexin-1-receptoren | |
FR3019749B1 (fr) | Autoinjecteur | |
DK3294283T3 (da) | Sacubitril-valsartan-doseringsregime til behandling af hjerteinsufficiens | |
DK3140353T3 (da) | En coating opløsning | |
DK3153508T3 (da) | Naphthofuranderivater til anvendelse som anticancermidler | |
BR112017000541A2 (pt) | derivados de piridazinona herbicidas | |
BR112017017193A2 (pt) | compostos herbicidas | |
BR112016029117A2 (pt) | compostos herbicidas | |
DK3191466T3 (da) | Azetidinyloxyphenylpyrrolidinforbindelser | |
DK3183363T3 (da) | Fremgangsmåde til bestemmelse af overlevelsesprognosen for en patient, der lider af pankreascancer | |
DK2904938T3 (da) | Modulær platform |